Frovatriptan is a highly potent and cerebroselective agonist of the 5-HT1B/1D receptors, demonstrating the greatest receptor potency among clinically used triptan compounds, and it robustly activates serotonergic signaling pathways to modulate cranial vasoconstriction and trigeminal neurotransmission relevant to migraine pathophysiology, while showing demonstrated clinical efficacy and, in certain predefined endpoints, superiority when administered during the headache phase of migraine attacks accompanied by aura, supporting the optimized pharmacodynamic profile for targeted antimigraine therapy and translational neuropharmacology research.